Peapack Gladstone Financial Corp lifted its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 0.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,382 shares of the biopharmaceutical company’s stock after buying an additional 322 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Celgene were worth $7,972,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Todd Asset Management LLC acquired a new position in Celgene during the first quarter valued at approximately $17,130,000. Groesbeck Investment Management Corp NJ grew its holdings in Celgene by 3.5% during the first quarter. Groesbeck Investment Management Corp NJ now owns 4,455 shares of the biopharmaceutical company’s stock valued at $554,000 after purchasing an additional 150 shares during the period. Marcus Capital LLC grew its holdings in Celgene by 1.5% during the first quarter. Marcus Capital LLC now owns 11,550 shares of the biopharmaceutical company’s stock valued at $1,437,000 after purchasing an additional 175 shares during the period. Independent Advisor Alliance grew its holdings in Celgene by 46.3% during the first quarter. Independent Advisor Alliance now owns 6,003 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 1,899 shares during the period. Finally, Premier Asset Managment LLC grew its holdings in Celgene by 5.0% during the first quarter. Premier Asset Managment LLC now owns 123,107 shares of the biopharmaceutical company’s stock valued at $15,318,000 after purchasing an additional 5,840 shares during the period. Institutional investors own 80.17% of the company’s stock.

Celgene Corporation (CELG) opened at $102.73 on Friday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market cap of $80,880.00, a P/E ratio of 16.02, a PEG ratio of 0.79 and a beta of 1.77. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 earnings per share. sell-side analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.

A number of research analysts recently issued reports on the stock. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a report on Wednesday, August 16th. Cantor Fitzgerald restated a “buy” rating and set a $162.00 price objective on shares of Celgene in a report on Tuesday, September 26th. Piper Jaffray Companies restated a “neutral” rating and set a $133.00 price objective on shares of Celgene in a report on Monday, October 23rd. Stifel Nicolaus decreased their price objective on shares of Celgene from $155.00 to $149.00 and set a “buy” rating for the company in a report on Friday, October 20th. Finally, Robert W. Baird cut shares of Celgene from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $162.00 to $136.00 in a report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company’s stock. Celgene presently has a consensus rating of “Buy” and an average target price of $139.57.

In other news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Peapack Gladstone Financial Corp Has $7.97 Million Stake in Celgene Corporation (CELG)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/08/peapack-gladstone-financial-corp-has-7-97-million-stake-in-celgene-corporation-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.